distance treatments only. It also has the great advantage of using amounts of Co60 which are available and can be supplied and renewed within our own country at the present time. ACKNOWLEDGMENTS I would like to express my thanks to Dr. Gwen Hilton for her valuable help and advice, and also for her permission to publish this report.
POLYCYTHEMIA RUBRA VERA has been treated with radioactive phosphorus for three and a half years at The London Hospital and I shall discuss the results in 18 patients. A great deal more experience is needed before we can predict confidently the duration of the response to therapy.
The blood-volume changes in polycythwemia rubra vera: Dr. G. W. Boden suggested that a study of the blood volume might explain why patients often claim great relief after administration of radioactive phosphorus while measurements of hlmoglobin or red cell count show little change. So far 27 estimations of blood volume have been made on 11 patients. I shall describe first a mild case. His red cell count was about 6,500,000, the total blood volume was normal, the venous himatocrit was 52% instead of the usual 45%. 5 mc of p32 were given by intravenous injection. Four months later the venous hematocrit was 45 % and the blood volume was unaltered. After a year the figures are still normal, but the red cell volume has begun to rise, the venous hematocrit being 47 %. In this patient the blood volume did not change and was within normal limits and therefore the findings in venous blood-the red cell count and heematocrit-provided an accurate index of the effect of p32,
In a more marked case the initial blood volume was above normal and haematocrit was 67 %. 5 mc of p32 caused a marked fall in red cell volume. The plasma volume increased and the total blood volume fell to normal limits. In this case the change in the total blood volume makes peripheral findings an inaccurate guide to the true extent of the improvement. Before treatment red cell volume in this patient was 180% of normal while the venous haematocrit was only 160% of normal. The change in total volume conceals about 20% of the alteration in red cell volume.
In a more severe case this effect may be very great, for example the third patient had severe polycythemia. His blood volume was very high at 7 litres with a high red cell count and a himatocrit of 74%. He was treated initially by venesection, 4 pints being removed during one month. Two months later his blood volume had hardly altered but the heematocrit and red cell count had fallen markedly. His symptoms were little changed. He was given radioactive phosphorus and four months later said he felt he was back to normal. There had been a slight further fall in the red cell count and hematocrit but his symptomatic relief was presumably mostly due to the dramatic fall in blood volume which was now within normal limits. For explanation see text.
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Proceedings of the Royal Sociey of Medicine 20 11 cases investigated, and the normal blood volume is represented in column 1 as a rectangle, the red cell volume being 2 litres, the total volume nearly 5 litres and the haematocrit 45 %. In a mild case (column 2) the hnmatocrit is raised and the total volume is normal. The normal total volume is usually maintained until the hamatocrit is somewhere between 55% and 65%. Once the total begins to rise the venous blood picture no longer reflects the true state of affairs. For example, in this case if the venous hematocrit is 65 % with the total normal (column 3), the red cell volume is 150% of normal. If, however, the total increases without further fall in plasma volume, the red cell volume is 175 % of normal (column 4). I should say that this is a minimal figure for our cases. With a himatocrit of 65 % I would expect the red cell volume to be at least double normal. This diagram, of course, presents the problem at its simplest. There are other factors; for example, some patients treated with radioactive phosphorus put on a great deal of weight and some of the changes observed are probably secondary to this. TIhese findings affect the interpretation of the red cell count and similar investigations made on the peripheral blood. They show that the laboratory findings will usually indicate the trend of events correctly, but that sometimes a marked fall in blood volume with little change in the red cell count may account for what seems a mysterious improvement in the patient's symptoms. The second point which comes out of these observations is that when the patient begins to relapse there may be little relation between the blood findings and the symptoms. We find that symptomatic relapse usually lags months behind the rise in the red cell count. This is understandable, for the symptoms seem to be related more often to the increase in blood volume than to the rise in the hnmatocrit, although this is not always the case.
Thirdly, I do not think that measurements of blood volume form a necessary part of the therapeutic control of the disease. In all our patients in whom the venous hwematocrit was reduced to normal limits by effective treatment the total blood volume fell to within the normal range. It may be accepted that if the peripheral blood findings can be made normal then the total blood volume is also normal. These observations have shown that in the management of a case of polycythannia the patient's symptoms, however vague and improbable, should receive careful consideration. If the change in his symptoms seems to bear little relation to the laboratory findings it does not necessarily follow that the patient is imagining his complaints. It also means that assessing the success of treatment may be very difficult. When I came to review the series in an attempt to assess the value of the treatment I found that the lack of correlation between the clinical findings and the laboratory report was fully appreciated by those directing the treatment. In the end I concluded that the only single factor which took account of all the items and provided the least unsatisfactory way of assessing therapy was the length of time which elapsed before a further dose of radioactive phosphorus was thought necessary. Table I shows the results of 8 cases which had no previous treatment. In 4 the results have been Senior Registrar, Sheffield National Centre for Radiotherapy THE purpose of this paper is not to suggest that radioactive phosphorus should be used as the treatment of choice in mycosis fungoides, but merely to describe some of the clinical and physical observations we were able to make on a small number of cases and to show that this method of treatment may be a useful therapeutic agent in the disseminated stages of this disease.
The localized tumours which occur can be satisfactorily treated or controlled for long periods by X-ray therapy. Invariably, however, a stage is reached when the condition fails to respond to therapy, visceral lesions develop, the patient's general condition deteriorates and progresses to a
